Xolair 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FRRF0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,629
Award facts
- Contract value 100% obligated
- $34,629.03 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $34.6K to DMS Pharmaceutical Group Inc. for 300 mg/2 mL syringes of Xolair, a biologic immunosuppressant medication, with performance completion scheduled for December 24, 2025. This firm fixed-price delivery order utilizes no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award was issued to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, which has maintained SAM registration since 2001 and serves as a critical supplier within the Department of Defense pharmaceutical supply chain.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a single-award contract valued at $500M with a completion date of December 31, 2036. The PPV-G GEN V represents a component of the broader $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supplying branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables to support Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across numerous prior delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FRRF0?
SPE2DR26FRRF0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FRRF0 worth?
The government has obligated $34,629 on SPE2DR26FRRF0.
Is contract SPE2DR26FRRF0 an order under another contract?
Yes. SPE2DR26FRRF0 is a delivery order under SPE2DR25D9238, an indefinite delivery contract.
Was contract SPE2DR26FRRF0 competed?
The extent of competition for SPE2DR26FRRF0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award